[{"address1": "225 Franklin Street", "address2": "Suite 2100", "city": "Boston", "state": "MA", "zip": "02110", "country": "United States", "phone": "857 284 8891", "website": "https://ateapharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 75, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jean-Pierre  Sommadossi Ph.D.", "age": 67, "title": "Founder, Chairman, CEO & President", "yearBorn": 1956, "fiscalYear": 2023, "totalPay": 1041575, "exercisedValue": 0, "unexercisedValue": 1692200}, {"maxAge": 1, "name": "Ms. Andrea J. Corcoran J.D.", "age": 61, "title": "CFO, Executive VP of Legal & Secretary", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 712484, "exercisedValue": 0, "unexercisedValue": 369000}, {"maxAge": 1, "name": "Mr. Wayne  Foster CPA", "age": 54, "title": "Executive VP of Finance & Chief Accounting Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 580463, "exercisedValue": 0, "unexercisedValue": 281690}, {"maxAge": 1, "name": "Dr. Janet M. J.  Hammond M.D., Ph.D.", "age": 63, "title": "Chief Development Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 789473, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Maria Arantxa Horga M.D.", "age": 55, "title": "Chief Medical Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 679584, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jonae R. Barnes", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ariyapadi N. Krishnaraj", "title": "Vice President of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adel  Moussa Ph.D.", "title": "Executive Vice President of Chemistry", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Xiao-Jian  Zhou Ph.D.", "title": "Executive Vice President of Early Stage Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John F. Vavricka", "age": 60, "title": "Chief Commercial Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 581108, "exercisedValue": 0, "unexercisedValue": 744450}], "auditRisk": 3, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.63, "open": 3.65, "dayLow": 3.575, "dayHigh": 3.67, "regularMarketPreviousClose": 3.63, "regularMarketOpen": 3.65, "regularMarketDayLow": 3.575, "regularMarketDayHigh": 3.67, "beta": 0.175, "forwardPE": -1.4085603, "volume": 79304, "regularMarketVolume": 79304, "averageVolume": 241259, "averageVolume10days": 202470, "averageDailyVolume10Day": 202470, "bid": 3.62, "ask": 3.65, "bidSize": 200, "askSize": 100, "marketCap": 305607616, "fiftyTwoWeekLow": 2.765, "fiftyTwoWeekHigh": 4.6, "fiftyDayAverage": 3.5948, "twoHundredDayAverage": 3.65, "currency": "USD", "enterpriseValue": -193737136, "floatShares": 60008002, "sharesOutstanding": 84422000, "sharesShort": 2491578, "sharesShortPriorMonth": 2373618, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0295, "heldPercentInsiders": 0.09679, "heldPercentInstitutions": 0.69567, "shortRatio": 12.05, "shortPercentOfFloat": 0.0414, "impliedSharesOutstanding": 84868704, "bookValue": 5.644, "priceToBook": 0.6413891, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -175996992, "trailingEps": -2.1, "forwardEps": -2.57, "enterpriseToEbitda": 1.567, "52WeekChange": 0.106707335, "SandP52WeekChange": 0.24014747, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AVIR", "underlyingSymbol": "AVIR", "shortName": "Atea Pharmaceuticals, Inc.", "longName": "Atea Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1604064600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2b022d91-ddb5-3459-9d51-2eb405756366", "messageBoardId": "finmb_252824153", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.62, "targetHighPrice": 6.88, "targetLowPrice": 6.88, "targetMeanPrice": 6.88, "targetMedianPrice": 6.88, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 502214016, "totalCashPerShare": 5.949, "ebitda": -123648000, "totalDebt": 2025000, "quickRatio": 18.867, "currentRatio": 19.023, "debtToEquity": 0.425, "returnOnAssets": -0.13646, "returnOnEquity": -0.32628, "freeCashflow": -8249000, "operatingCashflow": -121492000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]